RNA logoRNA
Avidity Biosciences Inc

1,590
Loading...
Loading...
News
all
press releases
RNA Stock Moves More Than 30% in a Week: What's Driving This Rally?
Avidity Biosciences surges 36% on reports that Novartis may eye a deal, with talks said to be early and interest from other suitors possible.
Zacks·11d ago
News Placeholder
More News
News Placeholder
Clene Inc. (CLNN) Reports Q2 Loss, Misses Revenue Estimates
Clene (CLNN) delivered earnings and revenue surprises of -59.18% and -73.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·22d ago
News Placeholder
Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Lags Revenue Estimates
Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of -8.80% and -58.90%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·23d ago
News Placeholder
Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates
Fate Therapeutics (FATE) delivered earnings and revenue surprises of +17.14% and +190.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·24d ago
News Placeholder
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates
Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of -13.79% and -9.64%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·29d ago
News Placeholder
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Beats Revenue Estimates
Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of +27.78% and +12.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·30d ago
News Placeholder
Novartis Reportedly Eyeing To Acquire Avidity Biosciences: But Retail Expects Management To Sell Only At Significant Premium
Novartis has been evaluating a bid for Avidity and expressed interest in an acquisition in recent weeks, FT reported.
Stocktwits·1mo ago
News Placeholder
Avidity, Dyne get Bernstein ratings as oligonucleotide muscle trials advance
investing.com·2mo ago
News Placeholder
Citi says SMid biotechs alternative to large caps as it starts coverage
Investing.com -- Citi has expanded its biopharmaceutical research coverage, initiating coverage on seven small- and mid-cap (SMid) biotechnology companies. Citi said SMid biotechs remain an attractive alternative to large-cap pharmaceutical firms, particularly amid healthcare policy uncertainties. Citi initiated coverage with Buy ratings on 89bio (NASDAQ:ETNB), price target $25. Apogee (NASDAQ:APOG), price target $95. Avidity, price target $70, BioNTech (NASDAQ:BNTX), price target $145. Kiniksa, price target $40. Kymera, price target $52
investing.com·6mo ago
News Placeholder
Avidity Biosciences to Participate in Upcoming Investor Conferences
Avidity Biosciences to Participate in Upcoming Investor Conferences Avidity Biosciences to Participate in Upcoming Investor Conferences PR Newswire SAN DIEGO, Feb. 25, 2025 SAN DIEGO, Feb. 25, 2025...
PR Newswire·6mo ago

Latest RNA News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.